Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

NCT03972722 | Unknown Phase 2

• 1 other identifier: YH-S001-05
• Study Type: interventional
• Target: 89
• Locations: 1 country
• Sites: 1

Brief Summary

Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.

Conditions

Cervical Cancer

Outcome Measures

Primary Outcomes (1)

• Objective response rate

  Based on an independent image assessment board

  within 27 Months after patient enrolled

Secondary Outcomes (5)

• PFS

  within 27 Months after patient enrolled

• DCR

  within 27 Months after patient enrolled

• DOR

  within 27 Months after patient enrolled

• OS

  within 3 years after patient enrolled.

• TTR

  within 27 Months after patient enrolled

Study Arms (1)

GLS-010

EXPERIMENTAL

Full-human anti-pd-1 monoclonal antibodies

Drug: GLS-010

Interventions

GLS-010 DRUG

Patients will be given 240mg GLS-010 every treatment.

Also known as: Full-human anti-pd-1 monoclonal antibodies

GLS-010

Eligibility Criteria

• Age: 18 Years - 75 Years
• Gender Eligibility Details: Female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Willingness to participate in the clinical trial; completely understanding and knowing about the study and signing the ICF; willingness and capability to comply with the requirements of the study.
• Female aged from 18 to 75 years (margin included).
• Cervical cancer patients with histologically confirmed PD-L1 positive (CPS ≥ 1).
• Recurrent or metastatic cervical cancer patients who progress after receiving≥ 1 chemotherapy or are resistant to chemotherapy.
• Based on RECIST 1.1, at least one measurable lesions, i.e. an extranodal lesion ≥10 mm in the longest diameter of cross-sectional areas or a lymph node lesion ≥ 15 mm in the shortest diameter of cross-sectional areas in CT or MRI test.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Life expectancy ≥ 12 weeks.
• Organ and hematopoietic function as defined below:
• Hemoglobin (HGB) ≥ 90 g/L; White blood cell (WBC) ≥ 3 X 109/L; Absolute neutrophil count (ANC) ≥ 1.5 X 109/L; Platelets (PLT) ≥ 100 X 109/L; Total bilirubin≤ 1.5×upper limit of normal (ULN); AST and ALT ≤ 2.5×ULN or, for hepatic dysfunction due to liver metastases, ≤ 5×ULN; Serum creatinine (Cr) ≤ 1.5 X ULN or a creatinine clearance (CrCl) ≥ 50 mL/min; International normalized ratio (INR) or activated partial thromboplastin time (aPTT)≤1.5×ULN;
• Female patients of childbearing potential should be willing to birth control after ICF signing, the course of the study, and 5 months after the last dose of study medication.
• Patients must agree to provide either an archival tumor tissue sample or fresh biopsy sample for baseline biomarker tissue analyses, including staining for PD-L1. If archival tissue is not available and the patient does not have biopsy-accessible tumor lesions, the patient will be excluded.

You may not qualify if:

• Prior therapy with an anti-PD1, anti-PDL1, anti-PDL2, anti-CD137 or anti-CTLA-4 agent (including Ipilimumab or any other drug specifically targeting T-cell co-stimulation or checkpoint pathways).
• Prior anti-tumor therapy,(including chemotherapy, targeted small molecule therapy , radiotherapy, immunotherapy, mAb therapy) , or treatment with investigational products having not been launched onto the market in China in other clinical trials within 4 weeks prior to the first dose.
• A past history of allergic reactions attributed to any macromolecular protein preparation/monoclonal antibody, or any other composition of the investigational product.
• Pregnancy or lactation.
• Patients with any autoimmune disease and received systemic therapy within 2 years (i.e. corticosteroids or immunosuppressive medications) \[i.e.,but not limited to, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or caused by radiotherapy and chemotherapy can be included), patients with vitiligo or asthma CR in Childhood, not requiring any intervention in adulthood are permitted to enroll; patients with asthma requiring a bronchiectasis intervention are not permitted to enroll\].
• Subjects that requires systemic corticosteroids (dose equivalent to or above 10 mg prednisone daily) or other immunosuppressive medications within 14 days prior to enrollment or for the course of the study.
• Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Having received a live vaccine within 4 weeks prior to the first dose of investigational drug.
• Having received a live anti-tumor vaccine, or anti-tumor treatment with immunostimulation.
• Serious medical illness, such as severe infections, uncontrollable diabetes mellitus, cardiovascular diseases (i.e., grade 3 or 4 congestive heart failure (New York Heart Association (NYHA)), ≥ grade 2 heart block, myocardial infarction, uncontrolled arrhythmias, or unstable angina within 6 months prior to screening, and cerebral infarction within 3 months prior to screening) or lung diseases (i.e. interstitial pneumonia, obstructive pulmonary disease and symptomatic bronchospasm).
• Patients with positive HBsAg and/or positive HBcAb with positive hepatitis B virus DNA\> 103 copies/mL, or positive hepatitis C virus antibody; or positive syphilis.
• A known history of human immunodeficiency virus (HIV) infection, or other acquired and congenital immune deficiency diseases.
• A known history of active tuberculosis within 1 year prior to the first dose of investigational drug.
• Presence of other malignant cancers within 5 years prior to enrollment. Patients with cured carcinoma in situ and cured skin basal cell carcinoma or cutaneous squamous cell carcinoma are eligible.
• Having undergone allogeneic hematopoietic stem cell transplantation or solid organ transplantation.

Sponsors & Collaborators

• Guangzhou Gloria Biosciences Co., Ltd.: lead

Study Sites (1)

Fudan University Shanghai Cancer Hospital

Shanghai, Shanghai Municipality, China

RECRUITING

Related Publications (1)

• Xia L, Wang J, Wang C, Zhang Q, Zhu J, Rao Q, Cheng H, Liu Z, Yin Y, Ai X, Gulina K, Zheng H, Luo X, Chang B, Li L, Liu H, Li Y, Lou G, Zhou Q, Zhu Y, Xiao Z, Tong J, Wang K, Chen J, Wang X, Song L, Wei Z, Ye Y, Zhu J, Wu X. Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study. Int J Gynecol Cancer. 2023 Dec 4;33(12):1861-1868. doi: 10.1136/ijgc-2023-004705.

  PMID: 37875323 DERIVED

MeSH Terms

Conditions

Uterine Cervical Neoplasms

Interventions

zimberelimab

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Study Officials

• Xiaohua Wu, MD

  Fudan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Xiaohua Wu, MD

CONTACT

8621-6417 5590; wu.xh@fudan.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 31, 2019
• First Posted: June 4, 2019
• Study Start: May 15, 2019
• Primary Completion: May 15, 2022
• Study Completion: May 15, 2023
• Last Updated: June 5, 2019

Record last verified: 2019-05

Locations

CN (1)